Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US

Abstract Introduction The aim of this study was to compare the estimated direct and indirect costs with aflibercept 8 mg and faricimab in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) over 5 years. Methods An economic model was developed to estimat...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Andreas Kuznik, Anna Coughlan, Amy Pinsent, Hector Toro-Diaz, Steven Sherman, Nimesh Patel
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2025-09-01
Serija:	Ophthalmology and Therapy
Teme:	Aflibercept Anti-VEGF therapy Costs Diabetic macular edema Faricimab Intravitreal injection
Online dostop:	https://doi.org/10.1007/s40123-025-01236-6
Oznake:	Označite Brez oznak, prvi označite!